LYMPHOMA, LARGE-CELL, ANAPLASTIC

Clinical trials for LYMPHOMA, LARGE-CELL, ANAPLASTIC explained in plain language.

Never miss a new study

Get alerted when new LYMPHOMA, LARGE-CELL, ANAPLASTIC trials appear

Sign up with your email to follow new studies for LYMPHOMA, LARGE-CELL, ANAPLASTIC, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 2 Terminated 1

Early trial tests new weapon against Tough-to-Treat blood cancers

Disease control Terminated

This was an early-stage safety study for an experimental drug called PF-08046045, designed for adults with advanced lymphomas that had stopped responding to other treatments. The main goal was to find a safe dose and understand the drug's side effects. The trial was terminated ea…

Matched conditions: LYMPHOMA, LARGE-CELL, ANAPLASTIC

Phase: PHASE1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

LYMPHOMA, LARGE-CELL, ANAPLASTIC

Get alerted when new LYMPHOMA, LARGE-CELL, ANAPLASTIC trials appear

Early trial tests new weapon against Tough-to-Treat blood cancers